glp-1 news november 25 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care Trump drug price deal: Burning
Description
Recently, Eli Lilly introduced a promising new oral GLP-1 receptor agonist called orforglipron, which has significantly piqued my professional curiosity.
An estimated 15 million Americans are currently taking semaglutide weight loss drugs, which are proven to impact alcohol consumption
Novo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India
This time, the discussion centered around GLP-1 therapies and the rapidly expanding field of incretin-based medicine.
Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs
Oscar Health launched a new health marketplace to connect consumers to major individual health insurance plans as well as supplemental coverage beyond what it sells.
